Changes in lipid parameters from baseline to Week 12 (modified-intention-to-treat population)
| Mean (SD) . | HeFH (n =603) . | Non-FH (n =318) . | Overall (N=921) . |
|---|---|---|---|
| Total cholesterol | |||
| Absolute change (mmol/L) | −2.7 (1.4) | −2.4 (1.0) | −2.6 (1.3) |
| Relative change (%) | −38.0 (16.1) | −38.8 (13.3) | −38.3 (15.2) |
| LDL-C | |||
| Absolute change (mmol/L) | −2.7 (1.3) | −2.3 (0.9) | −2.6 (1.2) |
| Relative change (%) | −53.4 (21.2) | −57.6 (17.4) | −54.8 (20.1) |
| HDL-C | |||
| Absolute change (mmol/L) | 0.0 (0.2) | 0.0 (0.2) | 0.0 (0.2) |
| Relative change (%) | 4.4 (18.3) | 4.4 (15.3) | 4.4 (17.3) |
| Non-HDL-C | |||
| Absolute change (mmol/L) | −2.7 (1.5) | −2.4 (1.3) | −2.6 (1.4) |
| Relative change (%) | −45.5 (33.1) | −46.7 (40.6) | −45.9 (35.8) |
| Triglycerides | |||
| Absolute change (mmol/L) | −0.2 (0.6) | −0.3 (0.6) | −0.2 (0.6) |
| Relative change (%) | −7.2 (34.2) | −10.3 (33.5) | −8.3 (34.0) |
| Mean (SD) . | HeFH (n =603) . | Non-FH (n =318) . | Overall (N=921) . |
|---|---|---|---|
| Total cholesterol | |||
| Absolute change (mmol/L) | −2.7 (1.4) | −2.4 (1.0) | −2.6 (1.3) |
| Relative change (%) | −38.0 (16.1) | −38.8 (13.3) | −38.3 (15.2) |
| LDL-C | |||
| Absolute change (mmol/L) | −2.7 (1.3) | −2.3 (0.9) | −2.6 (1.2) |
| Relative change (%) | −53.4 (21.2) | −57.6 (17.4) | −54.8 (20.1) |
| HDL-C | |||
| Absolute change (mmol/L) | 0.0 (0.2) | 0.0 (0.2) | 0.0 (0.2) |
| Relative change (%) | 4.4 (18.3) | 4.4 (15.3) | 4.4 (17.3) |
| Non-HDL-C | |||
| Absolute change (mmol/L) | −2.7 (1.5) | −2.4 (1.3) | −2.6 (1.4) |
| Relative change (%) | −45.5 (33.1) | −46.7 (40.6) | −45.9 (35.8) |
| Triglycerides | |||
| Absolute change (mmol/L) | −0.2 (0.6) | −0.3 (0.6) | −0.2 (0.6) |
| Relative change (%) | −7.2 (34.2) | −10.3 (33.5) | −8.3 (34.0) |
FH, familial hypercholesterolaemia; HDL-C, high-density lipoprotein cholesterol; HeFH, heterozygous familial hypercholesterolaemia; LDL-C, low-density lipoprotein cholesterol; SD, standard deviation.
Changes in lipid parameters from baseline to Week 12 (modified-intention-to-treat population)
| Mean (SD) . | HeFH (n =603) . | Non-FH (n =318) . | Overall (N=921) . |
|---|---|---|---|
| Total cholesterol | |||
| Absolute change (mmol/L) | −2.7 (1.4) | −2.4 (1.0) | −2.6 (1.3) |
| Relative change (%) | −38.0 (16.1) | −38.8 (13.3) | −38.3 (15.2) |
| LDL-C | |||
| Absolute change (mmol/L) | −2.7 (1.3) | −2.3 (0.9) | −2.6 (1.2) |
| Relative change (%) | −53.4 (21.2) | −57.6 (17.4) | −54.8 (20.1) |
| HDL-C | |||
| Absolute change (mmol/L) | 0.0 (0.2) | 0.0 (0.2) | 0.0 (0.2) |
| Relative change (%) | 4.4 (18.3) | 4.4 (15.3) | 4.4 (17.3) |
| Non-HDL-C | |||
| Absolute change (mmol/L) | −2.7 (1.5) | −2.4 (1.3) | −2.6 (1.4) |
| Relative change (%) | −45.5 (33.1) | −46.7 (40.6) | −45.9 (35.8) |
| Triglycerides | |||
| Absolute change (mmol/L) | −0.2 (0.6) | −0.3 (0.6) | −0.2 (0.6) |
| Relative change (%) | −7.2 (34.2) | −10.3 (33.5) | −8.3 (34.0) |
| Mean (SD) . | HeFH (n =603) . | Non-FH (n =318) . | Overall (N=921) . |
|---|---|---|---|
| Total cholesterol | |||
| Absolute change (mmol/L) | −2.7 (1.4) | −2.4 (1.0) | −2.6 (1.3) |
| Relative change (%) | −38.0 (16.1) | −38.8 (13.3) | −38.3 (15.2) |
| LDL-C | |||
| Absolute change (mmol/L) | −2.7 (1.3) | −2.3 (0.9) | −2.6 (1.2) |
| Relative change (%) | −53.4 (21.2) | −57.6 (17.4) | −54.8 (20.1) |
| HDL-C | |||
| Absolute change (mmol/L) | 0.0 (0.2) | 0.0 (0.2) | 0.0 (0.2) |
| Relative change (%) | 4.4 (18.3) | 4.4 (15.3) | 4.4 (17.3) |
| Non-HDL-C | |||
| Absolute change (mmol/L) | −2.7 (1.5) | −2.4 (1.3) | −2.6 (1.4) |
| Relative change (%) | −45.5 (33.1) | −46.7 (40.6) | −45.9 (35.8) |
| Triglycerides | |||
| Absolute change (mmol/L) | −0.2 (0.6) | −0.3 (0.6) | −0.2 (0.6) |
| Relative change (%) | −7.2 (34.2) | −10.3 (33.5) | −8.3 (34.0) |
FH, familial hypercholesterolaemia; HDL-C, high-density lipoprotein cholesterol; HeFH, heterozygous familial hypercholesterolaemia; LDL-C, low-density lipoprotein cholesterol; SD, standard deviation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
